Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Fineline Cube Jan 10, 2026
Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC

Fineline Cube Jan 11, 2026
Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Fineline Cube Jan 10, 2026
Company Deals R&D

Shanghai Fosun High Technology Partners with NICE for Joint Innovation Centers

Fineline Cube Jun 9, 2023

China-based conglomerate Shanghai Fosun High Technology (Group) Co., Ltd has entered into a partnership with...

Company Deals

Samyang Holdings Partners with Yxintent for Lafullen Dermal Filler in China

Fineline Cube Jun 9, 2023

South Korea-based Samyang Holdings Biopharm Group has secured a partnership with Hangzhou-based Yxintent, a specialist...

Deals

Sequoia Capital to Split into Three Units, Including Independent China and India/SEA Divisions

Fineline Cube Jun 8, 2023

US-based investment fund Sequoia Capital has declared plans to reorganize its business into three distinct...

Company Drug

Jacobio Pharma Gets Green Light for Phase I/IIa Study of PARP7 Inhibitor JAB-26766

Fineline Cube Jun 8, 2023

China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to initiate a Phase...

Company

BioMarin Pharmaceutical to Discontinue Vimizim Import License in China

Fineline Cube Jun 8, 2023

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced its decision not to renew the Import Drug...

Company Drug

Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS

Fineline Cube Jun 8, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...

Company Drug

Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023

Fineline Cube Jun 8, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...

Company Drug

Abbisko Therapeutics’ Pimicotinib Earns PRIME Status for TGCT from EMA

Fineline Cube Jun 8, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that its Category 1 drug...

Company Medical Device

NMPA Approves Shenzhen Core Medical’s Implantable Left Ventricular Assist System

Fineline Cube Jun 8, 2023

The National Medical Products Administration (NMPA) has issued market approval for the implantable left ventricular...

Company Deals

uBriGene Partners with Everlife Biomed to Advance iPSC Therapy Preparation

Fineline Cube Jun 8, 2023

China-based uBriGene, a leading cell and gene therapy contract development and manufacturing organization (CDMO), has...

Company

EpimAb Biotherapeutics Appoints Dr. Zhu Yonghong as Chief Medical Officer

Fineline Cube Jun 8, 2023

Shanghai-based biotech company EpimAb Biotherapeutics has announced the appointment of Dr. Zhu Yonghong to the...

Company Drug

CStone Pharmaceuticals and Servier Report Positive AGILE Study Results for Tibsovo at ASCO

Fineline Cube Jun 7, 2023

CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...

Company Drug

BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial

Fineline Cube Jun 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...

Company Drug

Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL

Fineline Cube Jun 7, 2023

Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...

Company Drug

ITabMed Ltd Receives NMPA IND Approval for A-337, a CD3-Activating BsAb Targeting EpCAM

Fineline Cube Jun 7, 2023

Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...

Policy / Regulatory

China’s MOST Issues Updated HGR Rules Impacting Foreign Collaborations in Genetic Research

Fineline Cube Jun 7, 2023

China’s Ministry of Science and Technology (MOST) has issued the “Detailed Implementation Rules for the...

Company Drug

Luye Pharma’s Lurbinectedin for Metastatic SCLC Accepted for Review by China’s NMPA

Fineline Cube Jun 7, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...

Company Deals Digital

Shanghai Runda Medical Science and Technology Partners with Huawei Cloud on AI in Healthcare

Fineline Cube Jun 7, 2023

China-based Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) is set to collaborate...

Company Drug

Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Announces FDA Review of NVK002 for Pediatric Myopia

Fineline Cube Jun 7, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Drug

Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma

Fineline Cube Jun 7, 2023

Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...

Posts pagination

1 … 457 458 459 … 606

Recent updates

  • Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal
  • Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC
  • Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D
  • Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy
  • InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Company Drug

Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC

Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.